Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.39
-1.5%
$0.38
$0.30
$3.33
$9.11M-1.37166,924 shs168,216 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.06
-1.9%
$1.12
$0.72
$8.25
$8.42M0.35348,546 shs213,055 shs
Biomerica, Inc. stock logo
BMRA
Biomerica
$3.12
-1.9%
$3.90
$1.93
$10.16
$7.94M0.37276,879 shs6,267 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.93
+1.1%
$0.78
$0.25
$8.90
$2.42M1.157,890 shs559 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-1.52%-5.60%-7.40%-43.44%-84.54%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-1.85%-10.17%-5.36%-32.91%-86.33%
Biomerica, Inc. stock logo
BMRA
Biomerica
-1.89%-11.11%-18.75%-48.62%-36.27%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
+1.08%+40.73%+17.88%-18.53%-81.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.7788 of 5 stars
3.55.00.00.02.91.70.0
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4.1402 of 5 stars
3.54.00.04.73.00.00.6
Biomerica, Inc. stock logo
BMRA
Biomerica
0.2518 of 5 stars
0.03.00.00.01.90.80.0
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$8.001,961.86% Upside
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
3.00
Buy$30.002,730.19% Upside
Biomerica, Inc. stock logo
BMRA
Biomerica
0.00
N/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VCNX, ACXP, BMRA, and BCLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$8.00
3/19/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$0.34 per shareN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.20) per shareN/A
Biomerica, Inc. stock logo
BMRA
Biomerica
$5.68M1.40N/AN/A$0.39 per share8.00
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K6.22N/AN/A($2.59) per share-0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)
Biomerica, Inc. stock logo
BMRA
Biomerica
-$5.98M-$2.32N/AN/A-100.52%-90.19%-64.54%N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/A-383.58%8/12/2025 (Estimated)

Latest VCNX, ACXP, BMRA, and BCLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
5/12/2025Q1 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.14-$0.11+$0.03-$0.11N/AN/A
4/14/2025Q3 2025
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A-$0.48N/A-$0.06N/A$1.12 million
3/17/2025Q4 2024
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.18-$0.16+$0.02-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Biomerica, Inc. stock logo
BMRA
Biomerica
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
1.80
1.80
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.05
0.05
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A
3.17
2.22
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Biomerica, Inc. stock logo
BMRA
Biomerica
22.28%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
29.60%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
6.70%
Biomerica, Inc. stock logo
BMRA
Biomerica
15.00%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
323.48 million11.99 millionOptionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
407.94 million5.32 millionOptionable
Biomerica, Inc. stock logo
BMRA
Biomerica
602.55 million15.59 millionOptionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex director resigns, no disagreement cited
Vaccinex to delist common stock from Nasdaq
Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval
Vaccinex receives delisting notification from Nasdaq
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex Shares Tumble 63% On Nasdaq Delisting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.39 -0.01 (-1.52%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.39 +0.00 (+0.26%)
As of 05/28/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.06 -0.02 (-1.85%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.06 +0.00 (+0.47%)
As of 05/28/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Biomerica stock logo

Biomerica NASDAQ:BMRA

$3.12 -0.06 (-1.89%)
Closing price 05/28/2025 03:55 PM Eastern
Extended Trading
$3.17 +0.05 (+1.73%)
As of 05/28/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.93 +0.01 (+1.08%)
As of 05/28/2025 11:47 AM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.